Since HMGB1 is overexpressed in breast cancer, TLR4 and AGER assessment offers a broader mechanistic perspective into innate immune activation and damage-associated inflammation, reinforcing the rationale for focusing on these markers. The gene discussed is TLR4; the disease is breast carcinoma.